汪鑫　 任晓岚　 尤启冬　 李志裕　

关键词：细胞周期蛋白依赖激酶(CDKs);细胞周期蛋白依赖激酶抑制剂;抗肿瘤
分类号：R979.1 　文献标识码：A
文章编号：1008-049X(2006)11-1052-03
 

    细胞周期和肿瘤的关系是近年来生命科学研究的热门课题之一.细胞周期调控异常与细胞癌变密切相关,在90%以上的人肿瘤中,尤其是胶质瘤和软组织肉瘤中细胞周期蛋白依赖激酶(CDKs)都有过度表达.因此,有人认为肿瘤是一种细胞周期疾病(cell cycle disease).近年来细胞周期调控最具突破性的进展,确定了细胞周期进程的分子机制,其核心机制为CDKs的活性表达与调控.本文将就细胞周期蛋白依赖性激酶及其抑制剂的研究进展作一综述.……
 

作者简介：汪鑫,男,硕士在读,主要从事化学治疗药物的研究.Tel:13914700080 E-mail:wangx_ku@tom.com
作者单位：汪鑫（中国药科大学药化教研室,南京,210009）　
　　　　　任晓岚（中国药科大学药化教研室,南京,210009）　
　　　　　尤启冬（中国药科大学药化教研室,南京,210009）　
　　　　　李志裕（中国药科大学药化教研室,南京,210009）　

参考文献：

[1]李峰,陈临溪.细胞周期蛋白D与细胞周期调控研究进展[J].国外医学·生理、病理科学与临床分册,2005,25(3):270-273
[2]刘芳.细胞周期与抗肿瘤治疗进展[J].国外临床生物化学与检验学分册,2002,23(4):202-203
[3]王鸿鹤.Cyclins/CDKs及其抑制剂的抗瘤作用[J].中国癌症杂志,2002,12(4):368-372
[4]罗蕴,胡永洲.细胞周期蛋白依赖性激酶抑制剂[J].中国现代应用药学杂志,2003,20(5):360-363
[5]Meijer L,Pondaven P.Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions.[J].Exp.Cell Res.,1988,174(1):116-129
[6]Schulze-Gahmen U,Brandsen J,Jones HD,et al.Multiple modes of ligand recognition:crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors,olomoucine and isopentenyladenine[J].Proteins,1995,22(4):378-391
[7]Rialet V,Meijer L.A new screening test for antimitotic compounds using the universal M phase-specific protein kinase,p34cdc2/cyclin Bcdc13,affinity-immobilized on p13sucl-coated microtitration plates.[J].AnticancerRes,1991,11(4):1581-1590
[8]Buolamwini JK.Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery[J].Current Pharmaceutical Design,2000,6(4):379-392
[9]Yun Dai,Steven Grant.Small Molecule Inhibitors Targeting Cyclin-dependent Kinases As Anticancer Agents[J].Curr Oncol Rep,2004,6(2):123-130
[10]Fischer,Peter M,Gianella-Borradori,et al.Recent progress in the discovery and development of cyclin-dependent kinase inhibitors[J].Expert Opinion on Investigational Drugs,2005,14 (4):457 -477
[11]Benson C,Kaye S,Workman P,et al.Clinical anticancer drug development:targeting the cyclin-dependent kinases[J].British Journal of Cancer,2005,92(1):7-12
[12]Peter M Fischer,Athos Gianella-Borradori.CDK inhibitors in clinical development for the treatment of cancer[J].Expert Opin Investig Drugs,2003,12(6):955-970
[13]农朝赞,黄华艺.黄酮类化合物对蛋白激酶的抑制作用[J].中国新药与临床杂志,2004,23(8):548-551
[14]Nam NH,Parang K.Current Targets for Anticancer Drug Discovery[J].Current Drug Targets,2003,4(2):159-179
[15]Benson C,Kaye S,Workman P,et al.Clinical anticancer drug development:targeting the cyclin-dependent kinases.[J].British Journal of Cancer,2005,92(1):7-12
[16]Smyth JF,Aamdal S,Awada A,et al.Phase Ⅱ study of E7070 in patients with metastatic melanoma[J].Annals of Oncology,2005,16(1):158-161
[17]Senderowicz AM.Flavopiridol:the first cyclin-dependent kinase inhibitor in human clinical trials[J].Invest.New Drugs,1999,17(3):313-320
[18]Aklilu M,Kindler HL,Donehower RC,et al.Phase Ⅱ study of flavopiridol in patients with advanced colorectal cancer[J].Annols of Oncology,2003,14(8):1270-1273
[19]蔡长春,刘瑾.抗癌中药及天然药物研究进展[J].中国药师,2001,4(4):254-256
[20]Ozawa Y,Sugi NH,Nagasu T,et al.E7070,a novel sulphonamide agent with potent antitumour activity in vitro and in vivo[J].Eur J Cancer,2001,37(17):2275-2282
[21]Haddad RI,Weinstein LJ,Wieczorek TJ,et al.A phase Ⅱ clinical and pharmacodynamic study of E7070 in patients with metastatic,recurrent,or refractory squamous cell carcinoma of the head and neck:modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor[J].Clinical Cancer Research,2004,10(14):4680-4687
[22]崔岚,王晓珉,安富荣.NF-κB、细胞凋亡与肿瘤治疗[J].中国药师,2003,6(12):777-779
[23]Partha Mukhopadhyay,Aktar AM,Animesh Nandi.The Cyclin-Dependent Kinase 2 Inhibitor Down-regulates Interleukin-1 β-Mediated Induction of Cyclooxygenase-2 Expression in Human Lung Carcinoma Cells[J].Cancer Res.,2006,66(3):1758-1766